gdc

Lung Cancer

Gavreto Second Drug FDA Approved for Patients with Metastatic Lung Cancer and RET Fusions
FDA Approvals, News & UpdatesLung Cancer
In September 2020, the FDA approved a second drug for the treatment of patients with lung cancer and RET fusions, improving the treatment options available today for patients with this type of lung cancer.
Beauty Is a Side Effect of (Lung) Cancer
Lung CancerPatient Stories
A.J. Patel, who ran around 20 miles a week as a semi-professional soccer referee, was shocked to get a lung cancer diagnosis and dismayed when his relationships strained. Then, an estranged uncle came to his aid.
New Therapies Improve Survival in Patients with Lung Cancer Associated with a Biomarker
BiomarkersLung Cancer
At the October 2020 conference of the European Society for Medical Oncology (ESMO), researchers presented information on new or recently approved targeted therapies and immunotherapies for lung cancer.
Retevmo First Drug FDA Approved for Patients with Metastatic Lung Cancer and RET Fusions
FDA Approvals, News & UpdatesLung Cancer
In May 2020, the FDA approved the first drug ever for the treatment of patients with lung cancer and RET fusions, a type of biomarker that can lead to lung cancer and requires specific drug therapy.
Oncogene Alterations Affect the Response to Targeted Therapies in Patients with Non–Small-Cell Lung Cancer and ALK Rearrangements
Lung Cancer
One biomarker that is involved in lung cancer is the ALK mutations. Although several drugs are now available for this type of lung cancer, new evidence shows that some patients may need different therapies.
Early Adjuvant Treatment with Tagrisso Improves Outcomes in Patients with Non–Small-Cell Lung Cancer and EGFR Mutations
Lung Cancer
Treatment with the targeted drug Tagrisso (osimertinib) as an adjuvant therapy (used in addition to primary therapy, such as surgery or chemotherapy) significantly reduces disease recurrence in patients with localized non–small-cell lung cancer (NSCLC) and an EGFR gene mutation (alteration).
Zepzelca, New Drug Approved for Metastatic  Small-Cell Lung Cancer, Has Fewer Side Effects  than Topotecan Chemotherapy
Lung Cancer
Zepzelca (lurbinectedin), a recently approved drug for patients with metastatic (spreading) small-cell lung cancer, may be even safer than expected, according to data from 2 studies presented at the 2020 ASCO annual meeting.
Tecentriq Improves Patient-Reported Outcomes in Advanced Non–Small-Cell Lung Cancer
Lung Cancer
Patients with metastatic (spreading to other parts of the body) non–small-cell lung cancer who received the drug Tecentriq (atezolizumab) as a first-line therapy had improvements in physical functioning, without worsening of their lung cancer–related symptoms, compared with patients who received chemotherapy.
Imfinzi plus Chemotherapy a New First-Line  Option for Patients with Extensive-Stage Small-Cell Lung Cancer
Lung Cancer
Patients with extensive-stage small-cell lung cancer, a rare type of lung cancer, now have a new first-line treatment option with Imfinzi (durvalumab), a PD-L1 inhibitor, in combination with chemotherapy, according to new results presented at the 2020 ASCO annual meeting. This new combination has been shown to improve survival for these patients, who do not have many treatment options and whose prognosis (survival outlook) is less than 5 years.
FDA Approves Cyramza plus Tarceva as First-Line Treatment of Metastatic NSCLC with EGFR Mutation
FDA Approvals, News & UpdatesLung Cancer
On May 29, 2020, the FDA approved the combination of Cyramza (ramucirumab; from Eli Lilly) in combination with Tarceva (erlotinib; from Astellas Pharma) for the first-line treatment of patients with metastatic non–small-cell lung cancer (NSCLC) and an EGFR exon 19 deletions or exon 21 (L858R) mutations.
Page 4 of 12
Results 31 - 40 of 113

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Gender
Race or Ethnicity
Profession or Role
Primary Interest